Abstract 481P
Background
SERDs are effective treatment options for breast cancer (BC) patients (pts) after progression on first-line therapy, especially for those harboring estrogen-receptor 1 (ESR1) mutations (mut). Several studies have explored the potential of SERDs to overcome endocrine resistance, yielding promising results.
Methods
We conducted a systematic review and meta-analysis to assess oral SERDs in hormone receptor-positive, HER-2-negative BC pts. Efficacy was evaluated by tumor response according to ESR1mut, and the number of pts with variant allele frequency (VAF) decreased with SERD therapy. We searched Pubmed, Scopus, and Cochrane Library databases and congress websites for randomized and non-randomized clinical trials. We used a random effects model for data pooling; heterogeneity was assessed with I2 statistics.
Results
We included 19 studies with 1,798pts. Of 855 pts tested, 387 (45%) had ESR1mut. ESR1mut frequency and respective overall response rate (ORR) are described in the table. We found 80% of pts(95%CI 0.72-0.88 I256%) had a decrease in VAF with SERD therapy. The estimated risk of all-causality adverse events (AE) was 86% (95% CI 0.80-0.92), and grades 3 or 4 AE were 19% (95% CI 0.11-0.28). SERD plus Palbociclib resulted in higher rates of AEs (p<0.01). Elacestrant had numerically higher G3-4 AEs compared to the other SERD (p=0.05). The most common AEs were nausea (35%), diarrhea (30%), and fatigue (23%). Arthralgia was reported in 15%, and only 1% of pts had to discontinue treatment due to AE.
Table: 481P
Characterization of ESR1mut and response to SERD (amcenestrant, elacestrant, and camizestrant)
ESR1mut | Prevalence of ESR1mut(%) | Patients assessed for response(n) | ORR(%) |
D538G | 34 | 25 | 44 |
Y537S | 28 | 23 | 61 |
E380Q | 8 | 8 | 25 |
Y537N | 7 | 11 | 45 |
L536H | 6 | 4 | 75 |
Others | 16 | 13 | 15 |
Conclusions
Our study supports the favorable safety profile of the new generation oral SERD and presents its efficacy according to ESR1mut. Further studies shall assess the potential biomarker role of individual ESR1mut.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Goldner Cesca: Financial Interests, Personal, Invited Speaker: Novartis, Daiichi Sankyo, Zodic. All other authors have declared no conflicts of interest.
Resources from the same session
489P - Liquid biopsy with combination of cell & cell-free analysis identifies HER2-expression in patients with metastatic breast cancer
Presenter: Fengting Yan
Session: Poster session 04
491P - Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
Presenter: Nina Dobrić
Session: Poster session 04
492P - Wound stress stimulation promotes lung metastasis of breast cancer by regulating CXCL12/CXCR4 axis through MDSC exosome miR-126a-5p
Presenter: Xiaomeng Yin
Session: Poster session 04
493P - Identifying genomic changes in breast tumours that metastasise to the brain
Presenter: Ivonne Olivares
Session: Poster session 04
494P - Proviral insertion in murine 1 (PIM1) kinase expression and clinical outcomes in advanced breast cancer (ABC)
Presenter: Stephanie Graff
Session: Poster session 04
495P - Prognostic value of PIK3CA mutational status in tissue & plasma in HR+/HER2- breast cancer (BC)
Presenter: Rebeca Lozano Mejorada
Session: Poster session 04
496P - Comprehensive genomic profiling of advanced HR+/HER2- breast cancer patients using liquid biopsy
Presenter: Bin Shao
Session: Poster session 04
497P - Metastatic potential of the somatic alteration associated with TCA-cycle in breast cancer
Presenter: Narumi Harada
Session: Poster session 04
1265P - Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial
Presenter: Shi Yan
Session: Poster session 04